As a result, Pfizer has maintained its stellar revenue growth outlook for the full-year 2022. The company expects total revenues to be between USD98bn and USD102bn, representing between 21% and 25% growth from 2021. We expect that significant income growth will provide Pfizer with significant cash on hand which can be used to fund inorganic business development activities that will replenish Pfizer's pipeline and fuel future growth.